Last 12 months
Inside the activity.
0 purchase rows · 65 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 9 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 8 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 12 |
| Jul 2026 | 0 | 6 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 21 |
| Oct 2026 | 0 | 3 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2021 Filed Mar 8, 2021 21:58 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 800 | $182.57 | $146,058.00 |
DisclosureSEC source: 0001713683-21-000039 · wf-form4_161524069989755.xml · nonDerivative · entry 7 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,492 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2020. F6 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $182.04 to $182.90, inclusive. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:58 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 1,454 | $181.19 | $263,450.26 |
DisclosureSEC source: 0001713683-21-000039 · wf-form4_161524069989755.xml · nonDerivative · entry 6 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,292 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2020. F5 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $180.91 to $181.70, inclusive. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:58 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 1,200 | $180.16 | $216,191.04 |
DisclosureSEC source: 0001713683-21-000039 · wf-form4_161524069989755.xml · nonDerivative · entry 5 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,746 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2020. F4 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $179.61 to $180.59, inclusive. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:58 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 400 | $178.80 | $71,518.00 |
DisclosureSEC source: 0001713683-21-000039 · wf-form4_161524069989755.xml · nonDerivative · entry 4 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,946 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2020. F3 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $178.23 to $179.08, inclusive. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:58 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 200 | $177.50 | $35,500.00 |
DisclosureSEC source: 0001713683-21-000039 · wf-form4_161524069989755.xml · nonDerivative · entry 3 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,346 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.20 to $177.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (10) to this Form 4. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:58 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 100 | $176.09 | $17,609.00 |
DisclosureSEC source: 0001713683-21-000039 · wf-form4_161524069989755.xml · nonDerivative · entry 2 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,546 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2020. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:58 UTC |
Sinha AmitDirector · President of R&D and CTO
|
Exercise / conversionCommon Stock | 7,000 | $5.93 | $41,475.00 |
DisclosureSEC source: 0001713683-21-000039 · wf-form4_161524069989755.xml · nonDerivative · entry 1 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2021 Filed Mar 3, 2021 22:59 UTC |
Brown Andrew William FraserDirector
|
SaleCommon Stock | 6,000 | $188.99 | $1,133,940.00 |
DisclosureSEC source: 0001713683-21-000034 · wf-form4_161481232547013.xml · nonDerivative · entry 1 Brown Andrew William Fraser · CIK 0001593803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,632 Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:19 UTC |
Sinha AmitDirector · President of R&D and CTO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $5.93 | $0.00 |
DisclosureSEC source: 0001713683-21-000028 · wf-form4_161402874730730.xml · derivative · entry 15 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,333 Underlying: Common Stock · 7,000 shares Expires 2027-04-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: One-fourth of the shares subject to the option vest on November 1, 2018 and 1/48 of the shares vest monthly thereafter. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:19 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 1,884 | $223.79 | $421,621.11 |
DisclosureSEC source: 0001713683-21-000028 · wf-form4_161402874730730.xml · nonDerivative · entry 8 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,646 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2020. F8 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $223.35 to $224.14, inclusive. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:19 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 600 | $222.99 | $133,791.00 |
DisclosureSEC source: 0001713683-21-000028 · wf-form4_161402874730730.xml · nonDerivative · entry 7 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,530 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2020. F7 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $222.34 to $223.29, inclusive. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:19 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 816 | $221.44 | $180,695.94 |
DisclosureSEC source: 0001713683-21-000028 · wf-form4_161402874730730.xml · nonDerivative · entry 6 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,130 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2020. F6 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $221.26 to $222.06, inclusive. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:19 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 2,000 | $220.51 | $441,010.00 |
DisclosureSEC source: 0001713683-21-000028 · wf-form4_161402874730730.xml · nonDerivative · entry 5 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,946 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2020. F5 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $220.00 to $220.97, inclusive. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:19 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 600 | $219.55 | $131,731.98 |
DisclosureSEC source: 0001713683-21-000028 · wf-form4_161402874730730.xml · nonDerivative · entry 4 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,946 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2020. F4 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $219.00 to $219.83, inclusive. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:19 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 900 | $218.23 | $196,407.27 |
DisclosureSEC source: 0001713683-21-000028 · wf-form4_161402874730730.xml · nonDerivative · entry 3 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,546 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2020. F3 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $217.62 to $218.51, inclusive. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:19 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 200 | $216.95 | $43,390.00 |
DisclosureSEC source: 0001713683-21-000028 · wf-form4_161402874730730.xml · nonDerivative · entry 2 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,446 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.46 to $217.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (8) to this Form 4. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:19 UTC |
Sinha AmitDirector · President of R&D and CTO
|
Exercise / conversionCommon Stock | 7,000 | $5.93 | $41,475.00 |
DisclosureSEC source: 0001713683-21-000028 · wf-form4_161402874730730.xml · nonDerivative · entry 1 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 00:19 UTC |
Sinha AmitDirector · President of R&D and CTO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $5.93 | $0.00 |
DisclosureSEC source: 0001713683-21-000023 · wf-form4_161248438377210.xml · derivative · entry 13 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,333 Underlying: Common Stock · 7,000 shares Expires 2027-04-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: One-fourth of the shares subject to the option vest on November 1, 2018 and 1/48 of the shares vest monthly thereafter. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 00:19 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 2,406 | $213.55 | $513,803.95 |
DisclosureSEC source: 0001713683-21-000023 · wf-form4_161248438377210.xml · nonDerivative · entry 6 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,646 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2020. F5 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $213.14 to $213.99, inclusive. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 00:19 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 3,000 | $212.65 | $637,944.90 |
DisclosureSEC source: 0001713683-21-000023 · wf-form4_161248438377210.xml · nonDerivative · entry 5 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,052 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2020. F4 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $212.13 to $213.10, inclusive. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 00:19 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 900 | $211.54 | $190,382.04 |
DisclosureSEC source: 0001713683-21-000023 · wf-form4_161248438377210.xml · nonDerivative · entry 4 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,052 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2020. F3 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $211.13 to $212.00, inclusive. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 00:19 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 394 | $210.54 | $82,950.79 |
DisclosureSEC source: 0001713683-21-000023 · wf-form4_161248438377210.xml · nonDerivative · entry 3 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,952 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.07 to $210.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 00:19 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 300 | $208.86 | $62,658.00 |
DisclosureSEC source: 0001713683-21-000023 · wf-form4_161248438377210.xml · nonDerivative · entry 2 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,346 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2020. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 00:19 UTC |
Sinha AmitDirector · President of R&D and CTO
|
Exercise / conversionCommon Stock | 7,000 | $5.93 | $41,475.00 |
DisclosureSEC source: 0001713683-21-000023 · wf-form4_161248438377210.xml · nonDerivative · entry 1 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 21:36 UTC |
Sinha AmitDirector · President of R&D and CTO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $5.93 | $0.00 |
DisclosureSEC source: 0001713683-21-000021 · wf-form4_161135138674923.xml · derivative · entry 13 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,333 Underlying: Common Stock · 7,000 shares Expires 2027-04-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: One-fourth of the shares subject to the option vest on November 1, 2018 and 1/48 of the shares vest monthly thereafter. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 21:36 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 203 | $217.75 | $44,202.97 |
DisclosureSEC source: 0001713683-21-000021 · wf-form4_161135138674923.xml · nonDerivative · entry 6 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,646 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2020. F6 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $217.50 to $217.99, inclusive. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 21:36 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 600 | $215.40 | $129,238.02 |
DisclosureSEC source: 0001713683-21-000021 · wf-form4_161135138674923.xml · nonDerivative · entry 5 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,849 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2020. F5 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $215.01 to $215.72, inclusive. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 21:36 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 1,100 | $214.57 | $236,025.02 |
DisclosureSEC source: 0001713683-21-000021 · wf-form4_161135138674923.xml · nonDerivative · entry 4 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,449 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2020. F4 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $214.00 to $214.99, inclusive. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 21:36 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 3,397 | $213.52 | $725,336.27 |
DisclosureSEC source: 0001713683-21-000021 · wf-form4_161135138674923.xml · nonDerivative · entry 3 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,549 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2020. F3 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $213.00 to $213.92, inclusive. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 21:36 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 1,700 | $212.57 | $361,366.45 |
DisclosureSEC source: 0001713683-21-000021 · wf-form4_161135138674923.xml · nonDerivative · entry 2 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,946 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.19 to $212.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 21:36 UTC |
Sinha AmitDirector · President of R&D and CTO
|
Exercise / conversionCommon Stock | 7,000 | $5.93 | $41,475.00 |
DisclosureSEC source: 0001713683-21-000021 · wf-form4_161135138674923.xml · nonDerivative · entry 1 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 22:42 UTC |
Sinha AmitDirector · President of R&D and CTO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $5.93 | $0.00 |
DisclosureSEC source: 0001713683-21-000013 · wf-form4_161014572086550.xml · derivative · entry 12 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,333 Underlying: Common Stock · 7,000 shares Expires 2027-04-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: One-fourth of the shares subject to the option vest on November 1, 2018 and 1/48 of the shares vest monthly thereafter. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 22:42 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 506 | $193.24 | $97,779.19 |
DisclosureSEC source: 0001713683-21-000013 · wf-form4_161014572086550.xml · nonDerivative · entry 6 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,646 Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 22:42 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 1,800 | $192.14 | $345,852.00 |
DisclosureSEC source: 0001713683-21-000013 · wf-form4_161014572086550.xml · nonDerivative · entry 5 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,152 Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 22:42 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 3,200 | $191.14 | $611,642.88 |
DisclosureSEC source: 0001713683-21-000013 · wf-form4_161014572086550.xml · nonDerivative · entry 4 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,952 Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 22:42 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 1,200 | $190.38 | $228,455.04 |
DisclosureSEC source: 0001713683-21-000013 · wf-form4_161014572086550.xml · nonDerivative · entry 3 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,152 Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 22:42 UTC |
Sinha AmitDirector · President of R&D and CTO
|
SaleCommon Stock | 294 | $185.87 | $54,644.99 |
DisclosureSEC source: 0001713683-21-000013 · wf-form4_161014572086550.xml · nonDerivative · entry 2 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,352 Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 22:42 UTC |
Sinha AmitDirector · President of R&D and CTO
|
Exercise / conversionCommon Stock | 7,000 | $5.93 | $41,475.00 |
DisclosureSEC source: 0001713683-21-000013 · wf-form4_161014572086550.xml · nonDerivative · entry 1 Sinha Amit · CIK 0001733850 · Director · President of R&D and CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2021 Filed Jan 7, 2021 21:51 UTC |
Schneider DavidDirector
|
GrantCommon Stock | 1,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001713683-21-000010 · wf-form4_161007425864484.xml · nonDerivative · entry 1 Schneider David · CIK 0001402350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,252 F1 · shares: The reported shares are represented by restricted stock units, which vest in four equal quarterly installments beginning on March 15, 2021. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 02:50 UTC |
Giancarlo Charles HDirector
|
GrantCommon Stock | 1,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001713683-21-000009 · wf-form4_161007423543115.xml · nonDerivative · entry 1 Giancarlo Charles H · CIK 0001299634 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,791 F1 · shares: The reported shares are represented by restricted stock units, which vest in four equal quarterly installments beginning on March 15, 2021. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 02:50 UTC |
BLASING KARENDirector
|
GrantCommon Stock | 1,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001713683-21-000007 · wf-form4_161007420125574.xml · nonDerivative · entry 1 BLASING KAREN · CIK 0001256358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,763 F1 · shares: The reported shares are represented by restricted stock units, which vest in four equal quarterly installments beginning on March 15, 2021. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 02:50 UTC |
Darling Scott CDirector
|
GrantCommon Stock | 1,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001713683-21-000008 · wf-form4_161007421915117.xml · nonDerivative · entry 1 Darling Scott C · CIK 0001733959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,430 F1 · shares: The reported shares are represented by restricted stock units, which vest in four equal quarterly installments beginning on March 15, 2021. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:42 UTC |
Brown Andrew William FraserDirector
|
GrantCommon Stock | 1,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001713683-21-000014 · wf-form4_161014573802349.xml · nonDerivative · entry 1 Brown Andrew William Fraser · CIK 0001593803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,819 F1 · shares: The reported shares are represented by restricted stock units, which vest in four equal quarterly installments beginning on March 15, 2021. Read SEC document |
| January 04, 2021 Filed Jan 4, 2021 22:39 UTC |
BLASING KARENDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $5.82 | $0.00 |
DisclosureSEC source: 0001713683-21-000002 · wf-form4_160979994124956.xml · derivative · entry 9 BLASING KAREN · CIK 0001256358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,334 Underlying: Common Stock · 3,000 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The shares subject to the options are fully vested and immediately exercisable. Read SEC document |
| January 04, 2021 Filed Jan 4, 2021 22:39 UTC |
BLASING KARENDirector
|
SaleCommon Stock | 100 | $199.71 | $19,971.00 |
DisclosureSEC source: 0001713683-21-000002 · wf-form4_160979994124956.xml · nonDerivative · entry 7 BLASING KAREN · CIK 0001256358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 595 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2020. Read SEC document |
| January 04, 2021 Filed Jan 4, 2021 22:39 UTC |
BLASING KARENDirector
|
SaleCommon Stock | 200 | $198.92 | $39,784.00 |
DisclosureSEC source: 0001713683-21-000002 · wf-form4_160979994124956.xml · nonDerivative · entry 6 BLASING KAREN · CIK 0001256358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 695 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2020. F6 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $198.67 to $199.17, inclusive. Read SEC document |
| January 04, 2021 Filed Jan 4, 2021 22:39 UTC |
BLASING KARENDirector
|
SaleCommon Stock | 300 | $196.91 | $59,073.99 |
DisclosureSEC source: 0001713683-21-000002 · wf-form4_160979994124956.xml · nonDerivative · entry 5 BLASING KAREN · CIK 0001256358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 895 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2020. F5 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $196.86 to $197.01, inclusive. Read SEC document |
| January 04, 2021 Filed Jan 4, 2021 22:39 UTC |
BLASING KARENDirector
|
SaleCommon Stock | 1,002 | $196.15 | $196,540.30 |
DisclosureSEC source: 0001713683-21-000002 · wf-form4_160979994124956.xml · nonDerivative · entry 4 BLASING KAREN · CIK 0001256358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,195 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2020. F4 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $195.67 to $196.66, inclusive. Read SEC document |
| January 04, 2021 Filed Jan 4, 2021 22:39 UTC |
BLASING KARENDirector
|
SaleCommon Stock | 400 | $194.76 | $77,904.00 |
DisclosureSEC source: 0001713683-21-000002 · wf-form4_160979994124956.xml · nonDerivative · entry 3 BLASING KAREN · CIK 0001256358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,197 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2020. F3 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $194.21 to $195.08, inclusive. Read SEC document |
| January 04, 2021 Filed Jan 4, 2021 22:39 UTC |
BLASING KARENDirector
|
SaleCommon Stock | 998 | $193.54 | $193,149.93 |
DisclosureSEC source: 0001713683-21-000002 · wf-form4_160979994124956.xml · nonDerivative · entry 2 BLASING KAREN · CIK 0001256358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,597 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $193.14 to $193.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.